Here, we report on the effect of stage, grade, mitotic index, and immunohistochemically detectable parameters (p53, HER2/neu, oestrogen and progesterone receptor status) on the outcome of a 90 patient subset of this well-defined, high-risk population of 114 patients, whose paraffin-embedded primary tumours were available for detailed analysis. The gene discussed is ERBB2; the disease is neoplasm.